PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma
Abstract Background Pazopanib, a multitargeted tyrosine kinase inhibitor, is recommended as the standard treatment for refractory soft tissue sarcoma (STS). However, there are comparatively few molecular determinants for predicting pazopanib efficacy. Based on correlative studies regarding the predi...
Furkejuvvon:
| Váldodahkkit: | , , , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
BMC
2021-03-01
|
| Ráidu: | BMC Cancer |
| Fáttát: | |
| Liŋkkat: | https://doi.org/10.1186/s12885-021-08069-z |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|